Precision Medicine in Oncology® Articles | Page 2

Precision Medicine a Necessary Component in HER2+ Breast Cancer Care
Mothaffar Fahed Rimawi, MD, discusses the significance of precision medicine in HER2-positive breast cancer, as well as the possible role of immunotherapy for this specific population.
Olaparib/Durvalumab Combo Effective for BRCA-mutant Breast Cancer
The combination of olaparib (Lynparza) and durvalumab (Imfinzi) demonstrated a disease control rate of 80% for pretreated patients with germline BRCA-mutated, HER2-negative metastatic breast cancer,
Trastuzumab Deruxtecan Impresses in HER2 Expressing Breast Cancers
Trastuzumab deruxtecan (ds-8201a), a HER2-targeting antibody-drug conjugate, demonstrated significant clinical activity in heavily pretreated patients with HER2-expressing metastatic breast cancers.
1-Year of Adjuvant Trastuzumab Remains Standard in HER2+ Breast Cancer
The phase III SOLD trial failed to demonstrate that DFS with 9 weeks of adjuvant trastuzumab was noninferior to the standard 12 months when the 2 regimens were combined with chemotherapy in women with early stage HER2-positive breast cancer.
Trastuzumab Disappoints in HER2-low Patient Cohort
A trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein has shown no significant efficacy, confounding investigators who launched the trial based on opposing results from 2 earlier studies.
Expert Emphasizes Importance of Neoadjuvant Therapy in HER2+ Breast Cancer
Patrick Borgen, MD, discusses the importance of neoadjuvant therapy in the treatment of patients with HER2-positive breast cancer.
Adjuvant Treatment Evolving for HER2+ Breast Cancer
Sara M. Tolaney, MD, discusses the state of adjuvant treatment for patients with HER2-positive breast cancer.
Expert Highlights Expanding Options for HER2+ Breast Cancer
Lajos Pusztai, MD, discusses neoadjuvant and adjuvant treatment decisions for patients with HER2-positive breast cancer, as well as the potential of immunotherapy in the metastatic setting.
Molecular Subtypes Prognostic for OS, DFS in Clear-Cell RCC
Four molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with striking differences seen in overall survival and disease-free survival between each of the groups.
Ramalingam Expands on Osimertinib Updates in NCCN Guidelines for EGFR+ NSCLC
Suresh A. Ramalingam, MD, discusses some of the changes to the NCCN guidelines in non-small cell lung cancer, specifically with EGFR-mutation–positive disease, and how the frontline recommendation of osimertinib will impact clinical practice.
Publication Bottom Border
Border Publication